Guggenheim Securities updated their outlook on Immunovant (NASDAQ:IMVT) shares, raising the price target from $44.00 to $46.00 while maintaining a Buy rating on the stock. Currently trading at $23.23, ...

RBC Capital analyst Rishi Jaluria maintained a Buy rating on Microsoft (MSFT – Research Report) on January 20 and set a price target of ...

Kurt Hallead, an analyst from Benchmark Co., maintained the Buy rating on Halliburton (HAL – Research Report). The associated price target ...

Bank of America analyst Lorraine Hutchinson reiterated a Buy rating on Bath & Body Works and maintained its $45 price target.

Stocks trading under $10 can be attractive for investors looking to scoop up some cheap shares. Unfortunately, quality stocks ...

Finally, Protagonist Therapeutics (NASDAQ:PTGX) has indicated that its financial runway extends beyond the fourth quarter of 2028, providing the company with a stable foundation to continue its ...

Stock ratings can range from simple “buy” and “sell” ratings to “equal weight” and “outperform” ratings. Here’s a quick overview of how analysts rate stocks. A “buy” rating ...

FinVolution's international expansion and low delinquency rates drive growth. See why FINV stock is a Strong Buy with a strong balance sheet and dividends.

Staszak has a bullish outlook on chicken demand in emerging markets as well. Argus has a "buy" rating and $60 price target for PPC stock, which closed at $45.53 on Jan. 13. Sun Life Financial is a ...

https://www.tipranks.com/news/the-fly/occ-issues-cease-and-desist-order-against-bank-of-america-for-bsa-deficiencies Citi kept a Buy rating on Inter&Co with an $8 ...